Immunization with a peptide epitope (p369-377) from HER-2/neu leads to peptide-specific cytotoxic T lymphocytes that fail to recognize HER-2/neu+ tumors.

Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma

1998 • 1,826 citations

Tyrosine Kinase Receptor with Extensive Homology to EGF Receptor Shares Chromosomal Location with neu Oncogene

1985 • 1,804 citations

The neu oncogene encodes an epidermal growth factor receptor-related protein

1986 • 1,131 citations

Cloning of the gene coding for a shared human melanoma antigen recognized by autologous T cells infiltrating into tumor.

1994 • 1,108 citations

Estrogen-dependent, tamoxifen-resistant tumorigenic growth of MCF-7 cells transfected with HER2/neu

1992 • 769 citations

Existent T-cell and antibody immunity to HER-2/neu protein in patients with breast cancer.

1994 • 467 citations

Impaired assembly and transport of HLA-A and -B antigens in a mutant TxB cell hybrid.

1986 • 437 citations

The use of anti-CD3 and anti-CD28 monoclonal antibodies to clone and expand human antigen-specific T cells

1990 • 353 citations

Induction of tumor-reactive CTL from peripheral blood and tumor-infiltrating lymphocytes of melanoma patients by in vitro stimulation with an immunodominant peptide of the human melanoma antigen MART-1.

1995 • 296 citations

Peptide vaccination can lead to enhanced tumor growth through specific T-cell tolerance induction.

1996 • 290 citations

The Multi-epitope Approach for Immunotherapy for Cancer: Identification of Several CTL Epitopes from Various Tumor-Associated Antigens Expressed on Solid Epithelial Tumors

1998 • 235 citations

Her-2/neu-derived peptides are tumor-associated antigens expressed by human renal cell and colon carcinoma lines and are recognized by in vitro induced specific cytotoxic T lymphocytes.

1998 • 227 citations

Vaccination with mutant ras peptides and induction of T-cell responsiveness in pancreatic carcinoma patients carrying the corresponding RAS mutation

1995 • 213 citations

Peptides derived from a wild-type murine proto-oncogene c-erbB-2/HER2/neu can induce CTL and tumor suppression in syngeneic hosts.

1997 • 157 citations

In vitro generation of human cytolytic T-cells specific for peptides derived from the HER-2/neu protooncogene protein.

1994 • 150 citations

Limit of T Cell Tolerance to Self Proteins by Peptide Presentation

1990 • 138 citations

Cytotoxic T Cells Isolated from Ovarian Malignant Ascites Recognize a Peptide Derived from the HER-2/neu Proto-oncogene

1993 • 124 citations

Identification of Her-2/Neu CTL epitopes using double transgenic mice expressing HLA-A2.1 and human CD.8

1997 • 107 citations

Induction of human cytotoxic T lymphocytes specific for prostate-specific antigen

1997 • 99 citations

Identification of overlapping epitopes in mutant ras oncogene peptides that activate CD4⁺ and CD8⁺ T cell responses

1996 • 59 citations

T-cell recognition of self peptides as tumor rejection antigens

1996 • 58 citations

Tumor-infiltrating lymphocytes from human ovarian cancer patients recognize autologous tumor in an MHC class II-restricted fashion.

1996 • 55 citations

Oligopeptide Induction of a Cytotoxic T Lymphocyte Response to HER-2/Neu Proto-oncogene in Vitro

1994 • 42 citations

Existent proliferative responses of peripheral blood mononuclear cells from healthy donors and ovarian cancer patients to HER-2 peptides.

1997 • 40 citations

TCR V beta 3+ and V beta 6+ CTL recognize tumor-associated antigens related to HER2/neu expression in HLA-A2+ ovarian cancers.

1994 • 37 citations

Mechanisms of escape from CD8+ T-cell clones specific for the HER-2/NEU proto-oncogene expressed in ovarian carcinomas: Related and unrelated to decreased MHC class 1 expression

1997 • 36 citations

Is C-ERB B-2 a predictor for recurrent disease in early stage breast cancer?

1994 • 23 citations